Biomarkers: The link between therapeutic drug monitoring and pharmacodynamics

Therapeutic Drug Monitoring

Volumn 28, Issue 1, 2006, Pages 35-38

  Oellerich, Michael ^a   Barten, Markus J ^b   Armstrong, Victor W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Calcineurin; Flow cytometry; Immunosuppression; Inosine monophosphate dehydrogenase; Lymphocyte activation markers

Indexed keywords

BIOLOGICAL MARKER; CALCINEURIN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INOSINE PHOSPHATE; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; CYCLOSPORIN; INOSINATE DEHYDROGENASE;

CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE; PRIORITY JOURNAL; SHORT SURVEY; BLOOD; DRUG ANTAGONISM; DRUG MONITORING; LYMPHOCYTE ACTIVATION; METHODOLOGY; ORGAN TRANSPLANTATION; REVIEW;

BIOLOGICAL MARKERS; CALCINEURIN; CYCLOSPORINE; CYTOKINES; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LYMPHOCYTE ACTIVATION; ORGAN TRANSPLANTATION;

EID: 33745492158     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000194503.85763.f5     Document Type: Short Survey

References (22)

1. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol. 2000;12:557-562.
2. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest. 1997;100:1894-1901.
3. Halloran PF, Helms LM, Kung L, et al. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999;68:1356-1361.
4. Grinyó JM, Cruzado JM, Millán O, et al. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation. 2004;78:1400-1403.
5. Langman LJ, LeGatt DF, Halloran PF, et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation. 1996;62:666-672.
6. Sanquer S, Breil M, Baron C, et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999;65:640-648.
7. Weigel G, Griesmacher A, Zuckermann AO, et al. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther. 2001;69:137-144.
8. Goldsmith D, Carrey EA, Edbury S, et al. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004;107:63-68.
9. Jain J, Almquist SJ, Ford PJ, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol. 2004;67:767-776.
10. Jagodzinski P, Lizakowski S, Smolenski RT, et al. Mycophenolate mofetil treatment following renal transplantation decreases GTP concentrations in mononuclear leucocytes. Clin Sci (Lond). 2004;107:69-74.
11. Budde K, Glander P, Bauer S, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med. 2000;38:1213-1216.
12. Glander P, Braun KP, Hambach P, et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem. 2001;34:543-549.
13. Budde K, Glander P, Hambach P, et al. Predictive value of pretransplant IMPDH activity for MMF dosing. Am J Transplant. 2004;4:651-654.
14. Stein CM, Murray JJ, Wood AJJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem. 1999;45:1477-1484.
15. Härtel C, Fricke L, Schumacher N, et al. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem. 2002;48:2225-2231.
16. Stadler M, Bîrsan T, Holm B, et al. Quantification of immunosuppression by flow cytometry in stable renal transplant recipients. Ther Drug Monit. 2003;25:22-27.
17. Sottong PR, Rosenbrock JA, Britz JA, et al. Measurement of T-lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol. 2000;7:307-311.
18. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant. 2003;17:77-88.
19. Gummert JF, Barten MJ, Sherwood SW, et al. Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. J Pharmacol Exp Ther. 1999;29:1100-1112.
20. Barten MJ, Gummert JF, Van Gelder T, et al. Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro. J Immunol Methods. 2001;253:95-112.
21. Barten MJ, Streit F, Boeger M, et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation. 2004;77:1154-1162.
22. Barten MJ, Shipkova M, Bartsch P, et al. Mycophenolic acid interaction with cyclosporine and tacrolimus in vitro and in vivo. Ther Drug Monit. 2005;27:123-131.